Kevin Suttmoeller, DO
Internal Medicine · Kansas City, MONPI 1144201914
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $161,465 of the $197,922 with a category attached, or 81.6%. Novo Nordisk accounts for 94.2% of it on its own, with 59 other manufacturers making up the rest. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 878 payments — averaging $225.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$186K
- AbbVie$2K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Regeneron Healthcare Solutions, Inc.$572
- GSK$538
- plus $6K from 54 others
What the payments were for
- Speaking & faculty fees$161,46582%
- Travel & lodging$19,32010%
- Food & beverage$17,0489%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$197,922 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $72,433 |
| MounjaroTirzepatide | 34 | $55,077 |
| JardianceEmpagliflozin | 42 | $54,743 |
| FarxigaDapagliflozin Propanediol | 43 | $38,272 |
| TrulicityDulaglutide | 23 | $31,039 |
| EliquisApixaban | 26 | $27,462 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,138 |
| GemtesaVibegron | 20 | $17,236 |
| LinzessLinaclotide | 11 | $13,071 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $8,015 |
| BelsomraSuvorexant | 16 | $6,818 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $6,203 |
| Novolog FlexpenInsulin Aspart | 33 | $5,846 |
| JanuviaSitagliptin Phosphate | 11 | $4,675 |
| Gabapentin | 139 | $3,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,142 | $86,11557 claims |
| Novo NordiskOzempic | $186,356 | $72,43355 claims |
| Boehringer IngelheimJardiance | $511 | $54,74342 claims |
| AstraZenecaFarxiga | $1,199 | $38,27243 claims |
| PfizerEliquis, Paxlovid | $379 | $28,91738 claims |
| GSKTrelegy Ellipta | $538 | $22,13826 claims |
| MerckBelsomra, Janumet, Januvia | $306 | $17,69638 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $180 | $17,23620 claims |
| AbbVieLinzess | $1,829 | $13,07111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $25 | $781117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Kansas City
- Craig DietzKansas City$226K
- Karla Houston-GrayKansas City$24K
- Kehinde MorohunfolaKansas City$16K
- David WiltKansas City$13K
- Jonathan SzetoKansas City$13K
- Timothy SmithSaint Peters$428K
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Dima DandachiColumbia$157K
- Justin SteinkampSaint Charles$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.